Citadel Advisors
OBIO icon

Citadel Advisors’s Orchestra BioMed OBIO Stock Holding History

Citadel Advisors’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-24,200
Closed -$100K – 13844
2025
Q4 		$100K Buy
+24,200
New +$97.6K ﹤0.01% 11638

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Citadel Advisors's OBIO Position: Q1 2026 in Review

Citadel Advisors increased its Orchestra BioMed (OBIO) stake by 162% in Q1 2026, buying an estimated $209K and bringing the position to 79,185 shares worth $337K. The position accounts for ﹤0.01% of the portfolio, ranked #10211.

Citadel Advisors first reported a position in OBIO in Q3 2020 and has held it in 21 quarters since. The position peaked at $3.34M in Q1 2023. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

  • Citadel Advisors held 79,185 shares of Orchestra BioMed worth $337K as of Q1 2026.
  • Citadel Advisors bought 49,010 Orchestra BioMed shares in Q1 2026, an estimated $209K.
  • Orchestra BioMed made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10211 holding.
  • Citadel Advisors first reported a position in Orchestra BioMed in Q3 2020 and has held it in 21 quarters since.
  • Citadel Advisors's Orchestra BioMed position peaked at $3.34M in Q1 2023.
  • 65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.